The growing market from GLP-1s
CNBC • • health
Key Points:
- GLP-1 weight-loss drugs like Mounjaro and Ozempic are causing temporary hair thinning and hair loss in some users, a side effect linked to rapid weight loss and nutrient changes.
- The surge in GLP-1 use—now taken by nearly 13% of U.S. adults and expected to reach 25 million by 2030—is driving increased demand for haircare products aimed at preventing or treating hair loss.
- Haircare brands such as Redken, Nutrafol, and KeraFactor are innovating and expanding product lines specifically for GLP-1 users, tapping into a growing market fueled by consumer stress and the desire for personalized solutions.
- Dermatologists note that hair loss from GLP-1 drugs resembles typical weight-loss-related shedding and often resolves over time, though it can cause significant emotional distress and increased demand for scalp and hair treatments.
- Industry experts highlight the unprecedented commercial opportunity in this space, with investors funding new haircare innovations and consumers expected to demonstrate strong loyalty due to the time hair treatments take to show results.
